These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 29296163)

  • 1. An evaluation of the cold chain technology in South-East, Nigeria using Immunogenicity study on the measles vaccines.
    Oli AN; Agu RU; Ihekwereme CP; Esimone CO
    Pan Afr Med J; 2017; 27(Suppl 3):28. PubMed ID: 29296163
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Measles vaccine potency and sero-conversion rates among infants receiving measles immunization in Ilorin, Kwara State, Nigeria.
    Fowotade A; Okonko IO; Nwabuisi C; Bakare RA; Fadeyi A; Adu FD
    J Immunoassay Immunochem; 2015; 36(2):195-209. PubMed ID: 24825255
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Enzyme-linked immunosorbent assay-IgG antibody avidity test for single sample serologic evaluation of measles vaccines.
    de Souza VA; Pannuti CS; Sumita LM; de Andrade Júnior HF
    J Med Virol; 1997 Jul; 52(3):275-9. PubMed ID: 9210036
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Live viral vaccine potency: an index for assessing the cold chain system.
    Adu FD; Adedeji AA; Esan JS; Odusanya OG
    Public Health; 1996 Nov; 110(6):325-30. PubMed ID: 8979747
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Potency status and efficacy of measles vaccine administered in Nigeria: a case study of three EPI centres in Lagos, Nigeria.
    Omilabu SA; Oyefolu AO; Ojo OO; Audu RA
    Afr J Med Med Sci; 1999; 28(3-4):209-12. PubMed ID: 11205835
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The cold chain and the expanded program on immunization in Chile: an evaluation exercise.
    Carrasco R; Dinstrans R; Montaldo I; Medina E; Reyes M; Vergara I; Piwonka A; Thomas ER
    Bull Pan Am Health Organ; 1982; 16(3):261-71. PubMed ID: 7171891
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Antibody persistence after primary measles-mumps-rubella vaccine and response to a second dose given at four to six vs. eleven to thirteen years.
    Johnson CE; Kumar ML; Whitwell JK; Staehle BO; Rome LP; Dinakar C; Hurni W; Nalin DR
    Pediatr Infect Dis J; 1996 Aug; 15(8):687-92. PubMed ID: 8858673
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Cost analysis of supplemental immunization activities to deliver measles immunization to children in Anambra state, south-east Nigeria.
    Sibeudu FT; Onwujekwe OE; Okoronkwo IL
    Vaccine; 2020 Aug; 38(37):5947-5954. PubMed ID: 32651114
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Feasible improvements in vaccines in the Expanded Programme on Immunization.
    McIntosh K
    Rev Infect Dis; 1989; 11 Suppl 3():S530-7. PubMed ID: 2669097
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aerosolized measles and measles-rubella vaccines induce better measles antibody booster responses than injected vaccines: randomized trials in Mexican schoolchildren.
    Bennett JV; Fernandez de Castro J; Valdespino-Gomez JL; Garcia-Garcia Mde L; Islas-Romero R; Echaniz-Aviles G; Jimenez-Corona A; Sepulveda-Amor J
    Bull World Health Organ; 2002; 80(10):806-12. PubMed ID: 12471401
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Measles outbreak in Ibadan: clinical, serological and virological identification of affected children in selected hospitals.
    Adu FD; Ikusika A; Omotade O
    J Infect; 1997 Nov; 35(3):241-5. PubMed ID: 9459395
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Low seroconversion rates to measles vaccine among children in Nigeria.
    Adu FD; Akinwolere OA; Tomori O; Uche LN
    Bull World Health Organ; 1992; 70(4):457-60. PubMed ID: 1394778
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The value of potency testing of poliomyelitis and measles vaccines as an integral part of cold chain surveillance.
    Saraswathy TS; Sinniah M; Lee WS; Lee PC
    Southeast Asian J Trop Med Public Health; 1993 Jun; 24(2):265-8. PubMed ID: 8266228
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Modelling the relative benefits of using the measles vaccine outside cold chain for outbreak response.
    Azam JM; Saitta B; Bonner K; Ferrari MJ; Pulliam JRC
    Vaccine; 2021 Sep; 39(40):5845-5853. PubMed ID: 34481696
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Program on immunization and cold chain monitoring: the status in eight health districts in Cameroon.
    Ateudjieu J; Kenfack B; Nkontchou BW; Demanou M
    BMC Res Notes; 2013 Mar; 6():101. PubMed ID: 23497720
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Immunogenicity and Efficacy of a Measles Virus-Vectored Chikungunya Vaccine in Nonhuman Primates.
    Rossi SL; Comer JE; Wang E; Azar SR; Lawrence WS; Plante JA; Ramsauer K; Schrauf S; Weaver SC
    J Infect Dis; 2019 Jul; 220(5):735-742. PubMed ID: 31053842
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preliminary results from direct-to-facility vaccine deliveries in Kano, Nigeria.
    Aina M; Igbokwe U; Jegede L; Fagge R; Thompson A; Mahmoud N
    Vaccine; 2017 Apr; 35(17):2175-2182. PubMed ID: 28364927
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Power cuts and EPI vaccine storage.
    Senanayake MP; Perera AS; De Silva TU
    Ceylon Med J; 1997 Jun; 42(2):69-71. PubMed ID: 9257464
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Assessment of factors affecting vaccine cold chain management practice in public health institutions in east Gojam zone of Amhara region.
    Bogale HA; Amhare AF; Bogale AA
    BMC Public Health; 2019 Nov; 19(1):1433. PubMed ID: 31675948
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Analysis and evaluation on quality of live attenuated measles vaccine from market surveillance sampling].
    Fang HH; Wang XX; Yi M
    Zhongguo Yi Miao He Mian Yi; 2009 Dec; 15(6):511-5. PubMed ID: 20518326
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.